Biomarker Deals: Terms Value and Trends 2019-2025
| 出版社 | BCC Research |
| 出版年月 | 2025年9月 |
| ページ数 | 125 |
| 図表数 | 127 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,650 |
| 種別 | 英文調査報告書 |
BCC Research（BCCリサーチ）「バイオマーカー取引：用語、価値、トレンド 2019-2025年 – Biomarker Deals: Terms Value and Trends 2019-2025」は、世界のバイオマーカー業界におけるライセンス、買収、提携を含む戦略的取引について、包括的に分析を行っています。2019年から2025年の間に締結された取引を対象として当レポートでは、バイオマーカー市場における新たなトレンド、投資行動、戦略的優先事項を詳説しています。
主な掲載内容
- エグゼクティブサマリー
- 市場概観
- 市場ダイナミクス
- 市場成長促進要因
- 市場成長阻害要因
- 市場機会
- 市場課題
- 新技術と発展
- 新技術
- ゲノミクス
- プロテオミクス
- メタボロミクス
- イメージング
- バイオインフォマティクス
- 買収、コラボレーション、ライセンス契約
- バイオマーカー市場におけるライセンス契約（2019～2025年）
- ライセンス契約の定義と概要
- 評価と支払い構造
- バイオマーカー市場におけるライセンス契約の分析（2019～2025年）
- バイオマーカー市場における買収（2019～2025年）
- 買収の定義と概要
- バイオマーカー市場における買収の分析（2019～2025年）
- バイオマーカー市場における提携／コラボレーション（2019～2025年）
- コラボレーションの定義と概要
- バイオマーカー市場における提携／コラボレーションの分析（2019～2025年）
- バイオマーカー市場における契約の詳細分析
- ライセンス契約の構造分析（2019～2025年）
- バイオマーカー業界における買収構造（2019～2025年）
- バイオマーカー市場における提携構造（2019～2025年）
- バイオマーカーの特許の状況
- 付録
- 調査手法
- 情報源
- 略語
- 企業情報
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- BAYER AG
- BD
- BIOFOURMIS
- BIOMERIEUX
- BIO-RAD LABORATORIES INC.
- BRUKER
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE LTD.
- ILLUMINA INC.
- MERCK KGAA
- QIAGEN
- REVVITY
- THERMO FISHER SCIENTIFIC INC.
Report Scope
This report, Biomarker Deals: Terms, Value and Trends 2019-2025, offers a comprehensive analysis of strategic transactions, encompassing licensing, acquisitions and collaborations, in the global biomarkers industry. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.
The chosen time frame reflects the factual nature of deal terms, values and structures, which cannot be accurately forecast. The report provides insights into terms of contracts, such as up-front payments, milestone-based compensation, royalty arrangements and termination clauses, supported by real-world case examples.
In addition to transaction analysis, the report provides an in-depth review of market dynamics, highlighting the drivers, restraints, opportunities and challenges influencing the market for biomarker development and commercialization. It also covers emerging technologies in the sector.
Overall, this report serves as a resource for prospective dealmakers seeking to understand the current state of biomarker partnerships. It offers actionable insights into how companies are structuring collaborations for the R&D and commercialization of biomarker technologies, supporting informed decision-making in this rapidly evolving field.
Report Includes
– An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including a comprehensive analysis of deal structures and their potential values
– Coverage of significant companies in this study, trends and obstacles and other information affecting the development of the biomarker market
– Review of business terms and conditions of deals in the market, with focus on major trends in deal-making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
– Information essential to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
– Information about the main elements in licensing, acquisitions and partnership deals in the biomarker industry
– Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis, et al.
– Details on various types of biomarkers deals and milestone payments and their value in different deals
– Analysis of the patent landscape featuring biomarkers
– Profiles of the leading companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Bio-Rad Laboratories Inc., and Agilent Technologies Inc.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Segments covered | Deal Type | ||||||||||||||||
| Key Market Drivers |
| ||||||||||||||||
| Companies studied |
| ||||||||||||||||
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Classification of Biomarkers
Examples of Biomarkers
Chapter 3 Market Dynamics
Overview
Market Drivers
Rising Incidence of Diseases
Advances in Omics and Imaging Technologies
Market Restraints
Development Costs
Need for Skilled Labor
Market Opportunities
Emerging Markets
Personalized Medicine
Market Challenges
Technical Challenges
Regulatory and Validation Complexity
Chapter 4 Emerging Technologies and Developments
Overview
Key Takeaways
Emerging Technologies
Genomics
Proteomics
Metabolomics
Imaging
Bioinformatics
Chapter 5 Acquisitions, Collaborations, and Licensing Deals
Licensing Deals in the Biomarker Market, 2019 to 2025
Definition and General Structure of Licensing Deals
Valuation and Payment Structure
Analysis of Licensing Deals in the Biomarker Market, 2019 to 2025
Acquisitions in the Biomarker Market, 2019 to 2025
Definition and General Structure of Acquisitions
Analysis of Acquisitions in the Biomarker Market, 2019 to 2025
Partnerships/Collaborations in Biomarker Market, 2019 to 2025
Definition and General Structure of Collaborations
Analysis of Partnerships/Collaborations in the Biomarkers Market, 2019 to 2025
Further Analysis of Deals in the Biomarker Market
Analysis of Structure of Licensing Deals, 2019 to 2025
Structure of Acquisitions in the Biomarker Industry, 2019 to 2025
Structure of Collaborations in the Biomarker Market, 2019 to 2025
Chapter 6 Biomarker Patent Landscape
Patent Landscape Takeaways
Patent Review
Chapter 7 Appendix
Methodology
Information Sources
Abbreviations
Company Profiles
ABBOTT
AGILENT TECHNOLOGIES INC.
BAYER AG
BD
BIOFOURMIS
BIOMERIEUX
BIO-RAD LABORATORIES INC.
BRUKER
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
ILLUMINA INC.
MERCK KGAA
QIAGEN
REVVITY
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table : Biomarker Licensing Deals, Acquisitions and Partnerships, by Type, 2021–2025
Table 1 : Categories of Biomarkers
Table 2 : Examples of Biomarkers
Table 3 : Forms of Payment in Licensing Deals
Table 4 : Number of Biomarker Licensing Deals in Biotech Sectors, 2019–2025
Table 5 : Biomarker Licensing Deals, 2019–2025
Table 6 : Number of Biomarker Licensing Deals in Pathological Sectors, 2019–2025
Table 7 : Goals of Biomarker Licensing Deals, 2019–2025
Table 8 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019–2025
Table 9 : Number of Biomarker Acquisitions in Biotech Sectors, 2019–2025
Table 10 : Biomarker Acquisitions, 2019–2025
Table 11 : Number of Biomarker Acquisitions in Different Pathological Sectors, 2019–2025
Table 12 : Goals of Biomarker Acquisitions, 2019–2025
Table 13 : Number of Biomarker Collaborations in Biotech Sectors, 2019–2025
Table 14 : Partnerships/Collaborations in the Biomarker Market, 2019–2025
Table 15 : Number of Biomarker Collaborations in Pathological Sectors, 2019–2025
Table 16 : Goals of Biomarker Collaborations, 2019–2025
Table 17 : Up-Front Payments in Licensing Deals in the Biomarker Market, 2019–2025
Table 18 : Milestone and Royalty Payments in Licensing Deals, 2019–2025
Table 19 : Termination Conditions in Licensing Deals, 2019–2024
Table 20 : Value of Biomarker Licensing Deals Worldwide, 2021–2025
Table 21 : Acquisitions in the Biomarker Industry, 2020–2024
Table 22 : Global Value of Biomarker Acquisitions, 2021–2025
Table 23 : Up-Front Payments and Total Value in Collaboration Deals, 2019–2025
Table 24 : Percentage of Up-Front Payments from Total Value in Collaborations, 2019–2025
Table 25 : Milestones and Royalty Payments in Collaborations in the Biomarker Market, 2019–2025
Table 26 : Number of Patents and Patent Applications Filed for Biomarkers, by Year, 2019–2024
Table 27 : Patents and Patent Applications Filed for Biomarkers, 2019–2024
Table 28 : Number of Patents and Patent Applications for Biomarkers, by Company, 2019–2024
Table 29 : Information Sources for this Report
Table 30 : Abbreviations Used in this Report
Table 31 : Abbott: Company Snapshot
Table 32 : Abbott: Financial Performance, FY 2023 and 2024
Table 33 : Abbott: Product Portfolio
Table 34 : Abbott: News/Key Developments, 2023 and 2024
Table 35 : Agilent Technologies Inc.: Company Snapshot
Table 36 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
Table 37 : Agilent Technologies Inc.: Product Portfolio
Table 38 : Agilent Technologies Inc.: News/Key Developments, 2023 and 2024
Table 39 : Bayer AG: Company Snapshot
Table 40 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 41 : Bayer AG: Product Portfolio
Table 42 : Bayer AG: News/Key Developments, 2024
Table 43 : BD: Company Snapshot
Table 44 : BD: Financial Performance, FY 2023 and 2024
Table 45 : BD: Product Portfolio
Table 46 : BD: News/Key Developments, 2024
Table 47 : Biofourmis: Company Snapshot
Table 48 : Biofourmis: Product Portfolio
Table 49 : Biofourmis: News/Key Developments, 2020 and 2024
Table 50 : bioMerieux: Company Snapshot
Table 51 : bioMerieux: Financial Performance, FY 2023 and 2024
Table 52 : bioMerieux: Product Portfolio
Table 53 : bioMerieux: News/Key Developments, 2024
Table 54 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 55 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
Table 56 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 57 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024
Table 58 : Bruker: Company Snapshot
Table 59 : Bruker: Financial Performance, FY 2023 and 2024
Table 60 : Bruker: Product Portfolio
Table 61 : Bruker: News/Key Developments, 2023
Table 62 : Danaher Corp.: Company Snapshot
Table 63 : Danaher Corp.: Financial Performance, FY 2023 and 2024
Table 64 : Danaher Corp.: Product Portfolio
Table 65 : Danaher Corp.: News/Key Developments, 2022–2024
Table 66 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 67 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 68 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 69 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
Table 70 : Illumina Inc.: Company Snapshot
Table 71 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 72 : Illumina Inc.: Product Portfolio
Table 73 : Illumina Inc.: News/Key Developments, 2024
Table 74 : Merck KGaA: Company Snapshot
Table 75 : Merck KGaA: Financial Performance, FY 2023 and 2024
Table 76 : Merck KGaA: Product Portfolio
Table 77 : Merck KGaA: News/Key Developments, 2024
Table 78 : Qiagen: Company Snapshot
Table 79 : Qiagen: Financial Performance, FY 2023 and 2024
Table 80 : Qiagen: Product Portfolio
Table 81 : Qiagen: News/Key Developments, 2023 and 2024
Table 82 : Revvity: Company Snapshot
Table 83 : Revvity: Financial Performance, FY 2023 and 2024
Table 84 : Revvity: Product Portfolio
Table 85 : Revvity: News/Key Developments, 2022 and 2023
Table 86 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 87 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 88 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 89 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024
List of Figures
Figure 1 : Market Dynamics Snapshot
Figure 2 : Share of Biomarker Licensing Deals, by Therapeutic Area, 2019–2025
Figure 3 : Share of Biomarker Licensing Deals, by Goal, 2019–2025
Figure 4 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019–2025
Figure 5 : Share of Biomarker Acquisitions in Pathological Sectors, 2019–2025
Figure 6 : Share of Biomarker Acquisitions, by Goal, 2019–2025
Figure 7 : Share of Biomarker Collaborations in Biotech Sectors, by Year, 2019–2025
Figure 8 : Share of Biomarker Collaborations in Pathological Sectors, 2019–2025
Figure 9 : Share of Biomarker Collaborations, by Goal, 2019–2025
Figure 10 : Share of Collaborations Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
Figure 11 : Abbott: Revenue Share, by Business Unit, FY 2024
Figure 12 : Abbott: Revenue Share, by Country/Region, FY 2024
Figure 13 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024
Figure 14 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024
Figure 15 : Bayer AG: Revenue Share, by Business Unit, FY 2024
Figure 16 : Bayer AG: Revenue Share, by Country/Region, FY 2024
Figure 17 : BD: Revenue Share, by Business Unit, FY 2024
Figure 18 : BD: Revenue Share, by Country/Region, FY 2024
Figure 19 : bioMérieux: Revenue Share, by Business Unit, FY 2024
Figure 20 : bioMérieux: Revenue Share, by Country/Region, FY 2024
Figure 21 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
Figure 22 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
Figure 23 : Bruker: Revenue Share, by Business Unit, FY 2024
Figure 24 : Bruker: Revenue Share, by Business Unit, FY 2024
Figure 25 : Danaher Corp.: Revenue Share, by Business Unit, FY 2024
Figure 26 : Danaher Corp.: Revenue Share, by Country/Region, FY 2024
Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 28 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 29 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 30 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 31 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
Figure 32 : Merck KGaA: Revenue Share, by Country/Region, FY 2024
Figure 33 : Qiagen: Revenue Share, by Business Unit, FY 2024
Figure 34 : Qiagen: Revenue Share, by Country/Region, FY 2024
Figure 35 : Revvity: Revenue Share, by Business Unit, FY 2024
Figure 36 : Revvity: Revenue Share, by Country/Region, FY 2024
Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2024
Figure 38 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2024
BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。
ライセンス別価格表
2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
新価格表
ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 4,650 | USD 5,580 | USD 6,696 | USD 8,035 |
ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,950 | USD 3,540 | USD 4,248 | USD 5,098 |
ライセンスタイプ3
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,500 | USD 3,000 | USD 3,600 | USD 4,320 |
旧価格表
旧ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 5,500 | USD 6,600 | USD7.920 | USD 9,504 |
旧ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 3,500 | USD 4,200 | USD 5,040 | USD 6,048 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- 2-5ライセンス
- 同一企業内5名までレポートファイルのご利用が可能です。
- サイトライセンス
- 同一企業同住所内でレポートファイルのご利用が可能です。
- エンタープライズライセンス
- 同一企業内人数無制限でレポートファイルのご利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後3営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
- 免疫療法薬の世界市場 2025-11-12
- 農業におけるAIの世界市場 2025-11-10
- 世界の電気アーク炉市場 2025-11-07
- 固体酸化物形燃料電池の技術と世界市場 2025-11-07
